Coherus Oncology (CHRS) Assets (2013 - 2026)
Coherus Oncology (CHRS) posted Assets of $266.0 million for Q1 2026, up 2.97% sequentially from $258.3 million in Q4 2025, and down 28.31% YoY from $371.1 million in Q1 2025.
Coherus Oncology (CHRS) Assets (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Assets for 14 years, with the latest figure at $266.0 million in Q1 2026.
- Quarterly Assets fell 28.31% year-over-year to $266.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $266.0 million (down 28.31% YoY) and the FY2025 annual result came in at $258.3 million, down 42.4% from the prior year.
- Assets advanced to $266.0 million in Q1 2026 per CHRS's latest filing, from $258.3 million in the prior quarter.
- Over five years, Assets peaked at $763.5 million in Q1 2024 and troughed at $258.3 million in Q4 2025.
- A 5-year average of $500.0 million and a median of $505.0 million in 2024 frame the typical range for Assets.
- The sharpest annual moves came in 2024 and 2025: Assets jumped 89.74% in 2024, then sank 51.4% in 2025.
- Over 5 years, Assets stood at $480.8 million in 2022, then soared by 30.94% to $629.6 million in 2023, then slipped by 28.76% to $448.5 million in 2024, then tumbled by 42.4% to $258.3 million in 2025, then grew by 2.97% to $266.0 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $266.0 million, $258.3 million, and $516.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Coherus Oncology | 203.82 Mn | 98.51 Mn | 10.07 Mn | 191.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 191.18 Mn |
| Mar 31, 2026 | 266.02 Mn |
| Dec 31, 2025 | 258.34 Mn |
| Sep 30, 2025 | 516.52 Mn |
| Jun 30, 2025 | 439.46 Mn |
| Mar 31, 2025 | 371.07 Mn |
| Dec 31, 2024 | 448.53 Mn |
| Sep 30, 2024 | 505.00 Mn |
| Jun 30, 2024 | 674.86 Mn |
| Mar 31, 2024 | 763.55 Mn |
| Dec 31, 2023 | 629.60 Mn |
| Sep 30, 2023 | 583.78 Mn |
| Jun 30, 2023 | 469.59 Mn |
| Mar 31, 2023 | 402.43 Mn |
| Dec 31, 2022 | 480.85 Mn |
| Sep 30, 2022 | 550.91 Mn |
| Jun 30, 2022 | 546.00 Mn |
| Mar 31, 2022 | 593.39 Mn |
| Dec 31, 2021 | 679.33 Mn |
| Sep 30, 2021 | 741.73 Mn |